The new Ryzen AI Max+ "Strix Halo" chips include the Ryzen AI Max+ 392 and Ryzen AI Max+ 388. Both feature boost speeds up to ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best healthcare AI stocks to buy now. On December 15, JPMorgan lowered its price target on Tempus AI, Inc. (NASDAQ:TEM) from $85 to $80. The firm maintained ...

In trading on Wednesday, shares of Tempus AI Inc (Symbol: TEM) crossed below their 200 day moving average of $67.03, changing hands as low as $66.66 per share. Tempus AI Inc shares are currently ...

Fintel reports that on November 25, 2025, BTIG maintained coverage of Tempus AI (NasdaqGS:TEM) with a Buy recommendation. Analyst Price Forecast Suggests 21.16% Upside As of November 17, 2025, the ...

Microsoft announced new agents for Word, Excel, and PowerPoint. They can help to shrink the gap between ideation and production. Other Copilot updates include an expanded Voice mode. In the era of AI ...

You don’t need to pay $30 per month for these latest Office AI features. You don’t need to pay $30 per month for these latest Office AI features. is a senior editor and author of Notepad, who has been ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

Gamma, a startup that creates AI-generated presentations, websites, and social media posts, announced on Monday a $68 million Series B round at a $2.1 billion valuation led by Andreessen Horowitz.

Tempus AI Inc. (NASDAQ:TEM) shares are trending on Wednesday. Check out the current price TEM of stock here. Shares of the healthcare technology company dropped 6.02% to $79.40 in after-hours trading ...

The smart money has taken a liking to Tempus AI (TEM). Though the mid-cap is choppy, the growth profile and recent margin gains are hard to ignore as applied AI looks to pick up more traction. Tempus ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the AI Stocks Making Waves on Wall Street. On October 20, Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating on the stock with a $110.00 price target.